Betamethasone Sodium Phosphate Injection Approved
January 9, 2026
Source: drugdu
35
On January 8th, Xianju Pharmaceutical...(002332) issued an announcement stating that the company recently received the "Drug Registration Certificate" for betamethasone sodium phosphate injection issued by the National Medical Products Administration.
The specification of betamethasone sodium phosphate injection is 1ml:4mg (calculated as CHFO), and it is submitted for approval as a Class 3 chemical drug. The reference preparation for this drug is betamethasone sodium phosphate injection marketed in the European Union, under the brand name Celestone®.
In the first three quarters of 2025, Xianju Pharmaceutical achieved revenue of RMB 2.826 billion and net profit attributable to the parent company of RMB 407 million.
https://finance.eastmoney.com/a/202601083613015592.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- OpenAI releases two AI products in the healthcare field. January 9, 2026
- Say goodbye to lifelong medication? Hepatitis B patients may be entering an era of “functional cure”. January 9, 2026
- Xuantai Pharmaceutical’s “Isaconazole Sulfate for Injection” has been approved for marketing by the National Medical Products Administration, enriching new options for antifungal treatment January 9, 2026
- Fosun Pharma resubmits its application for listing of Furuitinib January 9, 2026
- the treatment of generalized anxiety disorder January 9, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
